Cure My Disease

Don't miss your cure!

 Log in / Sign up

A drug that may curb bleeding during fibroid surgery faces its first big test

NCT ID NCT07721623

Disease control Sponsor: Alex Ekwueme Federal University Teaching Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 23, 2026 · Last updated Jul 24, 2026 · Updated 1 time

Summary

This trial tests whether a single injection of carbetocin, a longer-acting relative of oxytocin, can reduce blood loss in women undergoing open abdominal surgery to remove uterine fibroids. About 900 participants will be randomly assigned to receive carbetocin or a placebo, and doctors will compare changes in hemoglobin levels and the need for blood transfusions. If it works, carbetocin could offer a simple way to make fibroid surgery safer.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
a synthetic hormone drug called carbetocin, similar to oxytocin but longer-acting, given as an injection to help the uterus contract and reduce bleeding
What this could lead to
If effective, carbetocin could become a standard option to reduce blood loss and transfusion needs during fibroid removal surgery.
What could go wrong
This is an early-phase trial, so the drug may not prove more effective than current options. Possible risks include allergic reactions or side effects from the medication.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Early phase 1

The earliest testing in people: a first look at safety, in a very small group.

Participants

About 900 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Aug 2026

An estimate. Start dates often move.

Expected to finish

Aug 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

Children (under 18), adults (18 to 64) and older adults (65 and over)

Sex

Female participants only

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * All consented women booked for myomectomy. * No know allergy to Cabetocin. * Billed for open abdominal myomectomy. Exclusion Criteria: * Declined consent * Allergy to Cabetocin * Planned for additional uterotonic * Prior history of thromboembolism, * With bleeding disorders * History of renal disease * History of liver pathology * Chronic anaemia * Billed for vaginal or laparoscopic myomectomy * Patients received preoperative embolization or Gn-Rh analogue. * Type 8: Non-myometrial or ectopic

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Blood loss, surgical are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Blood Loss, Surgical Hemorrhage uterine corpus leiomyoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Blood loss, surgical

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.